News | June 24, 2024
Ascentage Pharma closes US$ 75 million equity investment by Takeda
Ascentage Pharma announces confidential submission of draft registration statement for proposed IPO
Ascentage Pharma announces confidential submission of draft registration statement for proposed IPO
Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes
Approval based on results from T2NOW, one of the largest paediatric type-2 diabetes Phase III trials to date
Abbott's first-of-its-kind i2i technology enables synchronized communication between two leadless pacemakers
his strategic collaboration with BluSim Tech marks a significant milestone in Fischer MVL's journey towards expanding its healthcare portfolio
DurA Cycle is designed for large-scale commercial manufacturing of monoclonal antibodies,
Oligonucleotides are a unique modality with potential to address hard-to-treat diseases with high unmet need
The transaction aligns with Lupin's strategy to grow its global presence in Specialty areas
Ulcerative Colitis (UC) is a chronic, idiopathic, immune-mediated inflammatory bowel disease (IBD) affecting the large intestine
Subscribe To Our Newsletter & Stay Updated
